Opinion|Videos|June 25, 2024
Non-adjuvant RSV Vaccine in Older Adults
Author(s)Carrie Koenigsfeld, PharmD, FAPhA
An RSV medical expert provides an overview of the RENOIR trial, which investigated the efficacy and safety of an adjuvanted RSV vaccine in adults aged 60 years and older, focusing on the vaccine's effectiveness in preventing RSV-associated lower respiratory tract infections and presenting other crucial findings from the study.
Advertisement
Episodes in this series
- The
RENOIR trial studied the safety and efficacy of non-adjuvanted vaccine in adults aged 60 years or older. What interim results were significant from this trial leading to the indication of the vaccine for this population?- Efficacy at preventing RSV-associated lower respiratory tract infections
- Adverse effects
- Trial limitations
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
2
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
3
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5
